Advertisement

Document › Details
Calyxt, Inc.. (5/22/18). "Press Release: Calyxt Announces Successful Closing of $60.9 Million Public Offering". Minneapolis, MN.
![]() |
Region | United States (USA) |
![]() |
Organisation | Calyxt Inc. (Nasdaq Global Market: CLXT) |
Group | Cellectis (Group) | |
Organisation 2 | Citigroup Global Markets Inc. | |
Group | Citigroup (Group) | |
![]() |
Product | TALEN (Transcription Activator-Like Effector Nuclease) |
Product 2 | investment banking | |
![]() |
Index term | Cellectis–SEVERAL: investment, 201805 public offering of Calyxt Inc $60.9m 4.6m+457k shares common stockat $15/share |
![]() |
Person | Moore, Jennifer (Cellectis 201511 VP Communications) |
Person 2 | Kasunich, Caitlin (KSCA Strategic Communications 201706) | |
Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) and Calyxt, Inc. (NASDAQ: CLXT) today announced the closing of Calyxt’s follow-on public offering of 4,057,500 shares of Calyxt’s common stock (inclusive of the full exercise by the underwriters of their option to purchase 457,500 additional shares) at a public offering price of $15.00 per share. The gross proceeds to Calyxt from the offering are approximately $60.9 million, before deducting the estimated expenses related to the offering and the underwriting discounts and commissions payable by Calyxt. Calyxt’s common stock is listed on the Nasdaq Global Market under the symbol “CLXT”.
Calyxt is a consumer-centric food- and agriculture-focused company. As of closing, Cellectis owns approximately 70.6% of Calyxt’s outstanding shares of common stock.
Citigroup, Goldman Sachs & Co. LLC and Jefferies acted as book-running managers for the offering. Wells Fargo Securities acted as lead manager and BMO Capital Markets Corp. acted as co-manager.
A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission and was declared effective on May 17, 2018. This offering was made only by means of a prospectus. A copy of the prospectus may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by facsimile at (212) 902-9316, or by email at prospectus-ny@ny.email.gs.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
For further information, please contact:
For Calyxt
Media contacts
Jennifer Moore, VP Communications
Phone: 917-580-1088
email: media@calyxt.com
Caitlin Kasunich / Nick Opich
KCSA Strategic Communications
212.896.1241 / 212.896.1206
email: ckasunich@kcsa.com / nopich@kcsa.com
Investor Relations contact
Simon Harnest, VP Corporate Strategy and Finance
Phone: 646-385-9008
email: simon.harnest@calyxt.com
Record changed: 2018-05-23 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for Cellectis (Group)
- [1] Cellectis S.A.. (10/29/19). "Press Release: First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma". New York, NY....
- [2] Cellectis S.A.. (10/1/19). "Press Release: Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates". Basel & New York, NY....
- [3] Allogene Therapeutics, Inc.. (12/3/18). "Press Release: Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting". South San Francisco,...
- [4] Cellectis S.A.. (9/19/18). "Press Release: CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board". New York, NY....
- [5] Cellectis S.A.. (9/18/18). "Press Release: Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP". Minneapolis, MN & New York, NY....
- [6] Cellectis S.A.. (6/12/18). "Press Release: Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports". New York....
- [7] Calyxt, Inc.. (5/15/18). "Press Release: Bayer CropScience, LP Agrees to Settle Lawsuit Filed by Calyxt in Delaware Chancery Court". Minneapolis, MN....
- [8] Cellectis S.A.. (5/7/18). "Press Release: Cellectis Reports 1st Quarter 2018 Financial Results". New York, NY....
- [9] Cellectis S.A.. (5/2/18). "Press Release: Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL)". New York, NY....
- [10] Cellectis S.A.. (5/1/18). "Press Release: Harvard’s Wyss Institute Partners with Cellectis to Recode the Human Genome". Boston, MA & New York, NY....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top